Annual CFO
-$107.29 M
-$3.56 M-3.43%
31 December 2023
Summary:
Celldex Therapeutics annual cash flow from operations is currently -$107.29 million, with the most recent change of -$3.56 million (-3.43%) on 31 December 2023. During the last 3 years, it has fallen by -$66.89 million (-165.55%). CLDX annual CFO is now -686.93% below its all-time high of $18.28 million, reached on 31 December 2008.CLDX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$55.34 M
-$26.01 M-88.69%
01 September 2024
Summary:
Celldex Therapeutics quarterly cash flow from operations is currently -$55.34 million, with the most recent change of -$26.01 million (-88.69%) on 01 September 2024. Over the past year, it has dropped by -$36.34 million (-191.35%). CLDX quarterly CFO is now -249.21% below its all-time high of $37.09 million, reached on 31 March 2006.CLDX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$157.84 M
-$36.34 M-29.91%
01 September 2024
Summary:
Celldex Therapeutics TTM cash flow from operations is currently -$157.84 million, with the most recent change of -$36.34 million (-29.91%) on 01 September 2024. Over the past year, it has dropped by -$61.31 million (-63.53%). CLDX TTM CFO is now -549.48% below its all-time high of $35.12 million, reached on 31 March 2006.CLDX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLDX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3.4% | -191.3% | -63.5% |
| 3 y3 years | -165.6% | -238.0% | -205.9% |
| 5 y5 years | -42.6% | -396.7% | -210.4% |
CLDX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -165.6% | at low | -281.0% | at low | -205.9% | at low |
| 5 y | 5 years | -165.6% | at low | -961.9% | at low | -290.6% | at low |
| alltime | all time | -686.9% | +5.1% | -249.2% | at low | -549.5% | at low |
Celldex Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$55.34 M(+88.7%) | -$157.84 M(+29.9%) |
| June 2024 | - | -$29.33 M(-27.8%) | -$121.49 M(+1.8%) |
| Mar 2024 | - | -$40.64 M(+24.9%) | -$119.36 M(+11.2%) |
| Dec 2023 | -$107.29 M(+3.4%) | -$32.53 M(+71.3%) | -$107.29 M(+11.2%) |
| Sept 2023 | - | -$18.99 M(-30.2%) | -$96.52 M(-14.4%) |
| June 2023 | - | -$27.20 M(-4.8%) | -$112.72 M(+4.6%) |
| Mar 2023 | - | -$28.57 M(+31.3%) | -$107.77 M(+3.9%) |
| Dec 2022 | -$103.73 M(+70.3%) | -$21.76 M(-38.2%) | -$103.73 M(+7.5%) |
| Sept 2022 | - | -$35.19 M(+58.2%) | -$96.49 M(+24.2%) |
| June 2022 | - | -$22.24 M(-9.3%) | -$77.67 M(+15.3%) |
| Mar 2022 | - | -$24.53 M(+68.9%) | -$67.36 M(+10.6%) |
| Dec 2021 | -$60.91 M(+50.7%) | -$14.52 M(-11.3%) | -$60.91 M(+18.0%) |
| Sept 2021 | - | -$16.37 M(+37.2%) | -$51.60 M(+9.6%) |
| June 2021 | - | -$11.93 M(-34.0%) | -$47.09 M(+1.5%) |
| Mar 2021 | - | -$18.08 M(+247.0%) | -$46.38 M(+14.8%) |
| Dec 2020 | -$40.40 M(-13.0%) | -$5.21 M(-56.1%) | -$40.40 M(-12.5%) |
| Sept 2020 | - | -$11.86 M(+5.7%) | -$46.19 M(+1.6%) |
| June 2020 | - | -$11.22 M(-7.3%) | -$45.47 M(+0.4%) |
| Mar 2020 | - | -$12.11 M(+10.1%) | -$45.29 M(-2.4%) |
| Dec 2019 | -$46.41 M(-38.3%) | -$11.00 M(-1.3%) | -$46.41 M(-8.7%) |
| Sept 2019 | - | -$11.14 M(+0.9%) | -$50.84 M(-6.0%) |
| June 2019 | - | -$11.04 M(-16.6%) | -$54.09 M(-10.5%) |
| Mar 2019 | - | -$13.23 M(-14.2%) | -$60.45 M(-19.7%) |
| Dec 2018 | -$75.23 M(-24.7%) | -$15.43 M(+7.2%) | -$75.23 M(-5.2%) |
| Sept 2018 | - | -$14.39 M(-17.3%) | -$79.33 M(-11.2%) |
| June 2018 | - | -$17.39 M(-37.9%) | -$89.30 M(-3.7%) |
| Mar 2018 | - | -$28.02 M(+43.5%) | -$92.69 M(-7.2%) |
| Dec 2017 | -$99.93 M(-11.6%) | -$19.52 M(-19.9%) | -$99.93 M(-0.8%) |
| Sept 2017 | - | -$24.36 M(+17.2%) | -$100.76 M(+0.4%) |
| June 2017 | - | -$20.79 M(-41.0%) | -$100.35 M(-11.5%) |
| Mar 2017 | - | -$35.26 M(+73.3%) | -$113.40 M(+0.3%) |
| Dec 2016 | -$113.04 M(+14.3%) | -$20.35 M(-15.1%) | -$113.04 M(+6.2%) |
| Sept 2016 | - | -$23.95 M(-29.2%) | -$106.43 M(-3.5%) |
| June 2016 | - | -$33.83 M(-3.1%) | -$110.27 M(+9.0%) |
| Mar 2016 | - | -$34.90 M(+153.9%) | -$101.20 M(+2.3%) |
| Dec 2015 | -$98.89 M(-2.6%) | -$13.74 M(-50.5%) | -$98.89 M(-7.9%) |
| Sept 2015 | - | -$27.79 M(+12.2%) | -$107.36 M(+1.1%) |
| June 2015 | - | -$24.76 M(-24.0%) | -$106.16 M(+3.8%) |
| Mar 2015 | - | -$32.59 M(+46.7%) | -$102.25 M(+0.7%) |
| Dec 2014 | -$101.54 M(+50.0%) | -$22.21 M(-16.5%) | -$101.54 M(+7.7%) |
| Sept 2014 | - | -$26.59 M(+27.5%) | -$94.28 M(+10.7%) |
| June 2014 | - | -$20.86 M(-34.6%) | -$85.14 M(+3.4%) |
| Mar 2014 | - | -$31.88 M(+113.1%) | -$82.34 M(+21.7%) |
| Dec 2013 | -$67.67 M(+35.9%) | -$14.96 M(-14.3%) | -$67.67 M(+2.5%) |
| Sept 2013 | - | -$17.45 M(-3.3%) | -$66.04 M(+10.9%) |
| June 2013 | - | -$18.06 M(+5.0%) | -$59.53 M(+11.4%) |
| Mar 2013 | - | -$17.20 M(+29.1%) | -$53.43 M(+7.3%) |
| Dec 2012 | -$49.78 M(+39.6%) | -$13.33 M(+21.8%) | -$49.78 M(+8.6%) |
| Sept 2012 | - | -$10.94 M(-8.5%) | -$45.83 M(+6.7%) |
| June 2012 | - | -$11.96 M(-11.8%) | -$42.94 M(+6.4%) |
| Mar 2012 | - | -$13.55 M(+44.6%) | -$40.35 M(+13.1%) |
| Dec 2011 | -$35.66 M(+17.4%) | -$9.37 M(+16.3%) | -$35.66 M(+10.4%) |
| Sept 2011 | - | -$8.06 M(-13.9%) | -$32.30 M(+1.0%) |
| June 2011 | - | -$9.37 M(+5.7%) | -$31.99 M(-1.0%) |
| Mar 2011 | - | -$8.86 M(+47.4%) | -$32.30 M(+6.3%) |
| Dec 2010 | -$30.37 M(+1.7%) | -$6.01 M(-22.3%) | -$30.37 M(-13.7%) |
| Sept 2010 | - | -$7.74 M(-20.0%) | -$35.20 M(+6.8%) |
| June 2010 | - | -$9.68 M(+39.4%) | -$32.96 M(+5.4%) |
| Mar 2010 | - | -$6.94 M(-36.0%) | -$31.26 M(+4.7%) |
| Dec 2009 | -$29.87 M(-263.4%) | -$10.84 M(+97.0%) | -$29.87 M(+68.4%) |
| Sept 2009 | - | -$5.50 M(-31.0%) | -$17.73 M(-16.4%) |
| June 2009 | - | -$7.97 M(+43.6%) | -$21.21 M(-224.5%) |
| Mar 2009 | - | -$5.55 M(-528.9%) | $17.04 M(-6.8%) |
| Dec 2008 | $18.28 M(-300.3%) | $1.29 M(-114.4%) | $18.28 M(+34.1%) |
| Sept 2008 | - | -$8.98 M(-129.7%) | $13.63 M(-50.6%) |
| June 2008 | - | $30.27 M(-802.9%) | $27.56 M(-351.4%) |
| Mar 2008 | - | -$4.31 M(+28.2%) | -$10.96 M(+20.1%) |
| Dec 2007 | -$9.13 M | -$3.36 M(-167.8%) | -$9.13 M(-81.1%) |
| Sept 2007 | - | $4.95 M(-160.0%) | -$48.38 M(-15.4%) |
| June 2007 | - | -$8.25 M(+234.1%) | -$57.20 M(+7.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2007 | - | -$2.47 M(-94.2%) | -$53.20 M(+290.0%) |
| Dec 2006 | -$13.64 M(+126.7%) | -$42.61 M(+1003.0%) | -$13.64 M(-143.9%) |
| Sept 2006 | - | -$3.86 M(-9.1%) | $31.05 M(+1.3%) |
| June 2006 | - | -$4.25 M(-111.5%) | $30.66 M(-12.7%) |
| Mar 2006 | - | $37.09 M(+1688.2%) | $35.12 M(-683.6%) |
| Dec 2005 | -$6.02 M(-41.9%) | $2.07 M(-148.8%) | -$6.02 M(-48.3%) |
| Sept 2005 | - | -$4.25 M(-2139.3%) | -$11.63 M(+12.0%) |
| June 2005 | - | $208.60 K(-105.2%) | -$10.38 M(-15.1%) |
| Mar 2005 | - | -$4.05 M(+14.4%) | -$12.24 M(+18.3%) |
| Dec 2004 | -$10.35 M(-11.9%) | -$3.54 M(+17.4%) | -$10.35 M(+2.5%) |
| Sept 2004 | - | -$3.01 M(+83.1%) | -$10.10 M(+3.0%) |
| June 2004 | - | -$1.64 M(-23.7%) | -$9.80 M(-9.4%) |
| Mar 2004 | - | -$2.16 M(-34.3%) | -$10.82 M(-7.8%) |
| Dec 2003 | -$11.74 M(-29.5%) | -$3.28 M(+20.7%) | -$11.74 M(+25.1%) |
| Sept 2003 | - | -$2.72 M(+2.4%) | -$9.38 M(-20.6%) |
| June 2003 | - | -$2.66 M(-13.6%) | -$11.82 M(-17.5%) |
| Mar 2003 | - | -$3.08 M(+231.9%) | -$14.33 M(-14.0%) |
| Dec 2002 | -$16.66 M(-20.0%) | -$927.10 K(-82.0%) | -$16.66 M(-21.4%) |
| Sept 2002 | - | -$5.16 M(-0.0%) | -$21.20 M(-2.7%) |
| June 2002 | - | -$5.16 M(-4.6%) | -$21.79 M(+3.9%) |
| Mar 2002 | - | -$5.41 M(-1.0%) | -$20.97 M(+0.7%) |
| Dec 2001 | -$20.83 M(+369.9%) | -$5.47 M(-5.0%) | -$20.83 M(+33.1%) |
| Sept 2001 | - | -$5.75 M(+32.6%) | -$15.65 M(+26.1%) |
| June 2001 | - | -$4.34 M(-17.7%) | -$12.41 M(+13.9%) |
| Mar 2001 | - | -$5.27 M(+1734.8%) | -$10.90 M(+145.9%) |
| Dec 2000 | -$4.43 M(-48.1%) | -$287.20 K(-88.6%) | -$4.43 M(-17.7%) |
| Sept 2000 | - | -$2.52 M(-11.0%) | -$5.38 M(+2.2%) |
| June 2000 | - | -$2.83 M(-336.2%) | -$5.27 M(+6.6%) |
| Mar 2000 | - | $1.20 M(-196.6%) | -$4.94 M(-42.1%) |
| Dec 1999 | -$8.54 M(-4.1%) | -$1.24 M(-48.4%) | -$8.54 M(+1.7%) |
| Sept 1999 | - | -$2.40 M(-4.0%) | -$8.40 M(-14.3%) |
| June 1999 | - | -$2.50 M(+4.2%) | -$9.80 M(+4.3%) |
| Mar 1999 | - | -$2.40 M(+118.2%) | -$9.40 M(+5.6%) |
| Dec 1998 | -$8.90 M(+15.6%) | -$1.10 M(-71.1%) | -$8.90 M(-10.1%) |
| Sept 1998 | - | -$3.80 M(+81.0%) | -$9.90 M(+22.2%) |
| June 1998 | - | -$2.10 M(+10.5%) | -$8.10 M(+8.0%) |
| Mar 1998 | - | -$1.90 M(-9.5%) | -$7.50 M(-2.6%) |
| Dec 1997 | -$7.70 M(-20.6%) | -$2.10 M(+5.0%) | -$7.70 M(+2.7%) |
| Sept 1997 | - | -$2.00 M(+33.3%) | -$7.50 M(-6.3%) |
| June 1997 | - | -$1.50 M(-28.6%) | -$8.00 M(-12.1%) |
| Mar 1997 | - | -$2.10 M(+10.5%) | -$9.10 M(-6.2%) |
| Dec 1996 | -$9.70 M(+22.8%) | -$1.90 M(-24.0%) | -$9.70 M(+40.6%) |
| Sept 1996 | - | -$2.50 M(-3.8%) | -$6.90 M(-10.4%) |
| June 1996 | - | -$2.60 M(-3.7%) | -$7.70 M(+2.7%) |
| Mar 1996 | - | -$2.70 M(-400.0%) | -$7.50 M(-5.1%) |
| Dec 1995 | -$7.90 M(-13.2%) | $900.00 K(-127.3%) | -$7.90 M(-31.3%) |
| Sept 1995 | - | -$3.30 M(+37.5%) | -$11.50 M(+12.7%) |
| June 1995 | - | -$2.40 M(-22.6%) | -$10.20 M(0.0%) |
| Mar 1995 | - | -$3.10 M(+14.8%) | -$10.20 M(+12.1%) |
| Dec 1994 | -$9.10 M(+65.5%) | -$2.70 M(+35.0%) | -$9.10 M(+23.0%) |
| Sept 1994 | - | -$2.00 M(-16.7%) | -$7.40 M(+12.1%) |
| June 1994 | - | -$2.40 M(+20.0%) | -$6.60 M(+11.9%) |
| Mar 1994 | - | -$2.00 M(+100.0%) | -$5.90 M(+7.3%) |
| Dec 1993 | -$5.50 M(+41.0%) | -$1.00 M(-16.7%) | -$5.50 M(+22.2%) |
| Sept 1993 | - | -$1.20 M(-29.4%) | -$4.50 M(-6.3%) |
| June 1993 | - | -$1.70 M(+6.3%) | -$4.80 M(+14.3%) |
| Mar 1993 | - | -$1.60 M(+6.7%) | -$4.20 M(-4.5%) |
| Dec 1992 | -$3.90 M(-4.9%) | - | - |
| Oct 1992 | - | -$1.50 M(+36.4%) | -$4.40 M(0.0%) |
| July 1992 | - | -$1.10 M(-15.4%) | -$4.40 M(+7.3%) |
| Apr 1992 | - | -$1.30 M(+160.0%) | -$4.10 M(+41.4%) |
| Apr 1992 | -$4.10 M(+36.7%) | - | - |
| Jan 1992 | - | -$500.00 K(-66.7%) | -$2.90 M(-14.7%) |
| Oct 1991 | - | -$1.50 M(+87.5%) | -$3.40 M(-2.9%) |
| July 1991 | - | -$800.00 K(+700.0%) | -$3.50 M(+16.7%) |
| Apr 1991 | -$3.00 M(+328.6%) | -$100.00 K(-90.0%) | -$3.00 M(+3.4%) |
| Jan 1991 | - | -$1.00 M(-37.5%) | -$2.90 M(+52.6%) |
| Oct 1990 | - | -$1.60 M(+433.3%) | -$1.90 M(+533.3%) |
| July 1990 | - | -$300.00 K | -$300.00 K |
| Apr 1990 | -$700.00 K | - | - |
FAQ
- What is Celldex Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Celldex Therapeutics?
- What is Celldex Therapeutics annual CFO year-on-year change?
- What is Celldex Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly CFO year-on-year change?
- What is Celldex Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Celldex Therapeutics?
- What is Celldex Therapeutics TTM CFO year-on-year change?
What is Celldex Therapeutics annual cash flow from operations?
The current annual CFO of CLDX is -$107.29 M
What is the all time high annual CFO for Celldex Therapeutics?
Celldex Therapeutics all-time high annual cash flow from operations is $18.28 M
What is Celldex Therapeutics annual CFO year-on-year change?
Over the past year, CLDX annual cash flow from operations has changed by -$3.56 M (-3.43%)
What is Celldex Therapeutics quarterly cash flow from operations?
The current quarterly CFO of CLDX is -$55.34 M
What is the all time high quarterly CFO for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly cash flow from operations is $37.09 M
What is Celldex Therapeutics quarterly CFO year-on-year change?
Over the past year, CLDX quarterly cash flow from operations has changed by -$36.34 M (-191.35%)
What is Celldex Therapeutics TTM cash flow from operations?
The current TTM CFO of CLDX is -$157.84 M
What is the all time high TTM CFO for Celldex Therapeutics?
Celldex Therapeutics all-time high TTM cash flow from operations is $35.12 M
What is Celldex Therapeutics TTM CFO year-on-year change?
Over the past year, CLDX TTM cash flow from operations has changed by -$61.31 M (-63.53%)